Govorestat: FDA Approval Status and Its Role in Treating Galactosemia

Govorestat is a central nervous system penetrant Aldose Reductase Inhibitor (ARI) developed by Applied Therapeutics, Inc. for the treatment of galactosemia, a rare metabolic disease caused by the inability to break down galactose, leading to neurological complications and other health issues.

Galactosemia results in the accumulation of galactitol, a toxic metabolite, causing deficiencies in speech, cognition, behavior, and motor skills, alongside juvenile cataracts and ovarian insufficiency in women. Govorestat aims to inhibit the enzyme aldose reductase, crucial in converting galactose into galactitol, thereby addressing the root cause of galactosemia.

Despite its potential, the FDA has not approved Govorestat, as indicated by a Complete Response Letter (CRL) issued on November 27, 2024. The CRL highlighted deficiencies in the clinical application, preventing the approval of the New Drug Application (NDA) for the treatment of classic galactosemia. The NDA had been granted Priority Review status with a PDUFA target action date of November 28, 2024.

Govorestat has received several designations from the FDA, including Orphan Drug Designation for galactosemia, PMM2-CDG, and SORD deficiency; Pediatric Rare Disease designation for galactosemia and PMM2-CDG; and Fast Track designation for galactosemia, underscoring its potential in treating these rare conditions.

This development underscores the challenges in bringing new treatments for rare diseases to market, despite their potential to address significant unmet medical needs.